12.00-12.10  

prof. MACIEJ MAŁECKI 

Jagiellonian University, Kraków, Poland
 
prof.  ARTUR JURCZYSZYN

Jagiellonian University, Kraków, Poland

opening the international  conference

Chairmen of the Session nr I 

prof. Sebastian Grosicki 
prof. Aleksander Skotnicki
dr Wojciech Legieć 

12.10-12.30

prof. THIERRY FACON

University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

 “Practical aspects of immunotherapy in 2027”  

12.30-12.40

 discussion

12.40-13.00

prof. ALESSANDRO GOZZETTI

University of Siena, Italy

  “Management of renal failure in plasma cell dyscrasias”

13.00-13.10

discussion

13.10 13.30

prof. JENS HILLENGASS

Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

 “Navigating Modern Imaging Guidelines in Multiple Myeloma: Evidence vs. Real-World Practice”  

13.30-13.40

discussion

13.40-14.00

prof. MICHAELA HILLENGASS

Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

 “Physical activity in multiple myeloma”  

14.00-14.15

discussion

14.15-15.00

COFFE BREAK 

Chairmen of the Session nr II

prof. Tomasz Sacha
dr hab. Grzegorz Charliński
dr Paweł Steckiewicz

15.00-15.20

prof.  MICHEL DELFORGE

Department of Hematology, Leuven University Hospital, Leuven, Belgium

 “Navigating Relapsed and Refractory Multiple Myleoma: Treatment Options and Sequencing in 2027”

15.20-15.30

discussion

15.30-15.50

prof.  GABOR MIKALA

Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary

“CELMoDs in Multiple Myleoma: Where Do They Fit in the Evolving Treatment Landscape”

15.50-16.00

discussion

16.00-16.20 

prof.  ARTUR JURCZYSZYN

Jagiellonian University, Kraków, Poland

 “The price of progress: managing treatment-related toxicity in multiple myleoma"